| Document |
Document Title |
|
WO/2023/234407A1 |
An oral vaccine composition against a porcine circovirus-related disease, the oral vaccine composition comprising a pupa or a cell of a baculovirus infectious insect that has been subjected to an infection treatment with a recombinant ba...
|
|
WO/2023/232917A1 |
The invention relates to novel compounds having the general formula (Ib) or (Ib'), (Ib) or (Ib') wherein R1, R2, R6, A3, A4, A5, X, Y and W are as described herein, composition including the compounds and methods of using the compounds.
|
|
WO/2023/232054A1 |
Provided are a traditional Chinese medicine composition for treating cardiorenal syndrome and cardiac failure and a method for preparing same. The traditional Chinese medicine composition is prepared from the following raw materials: 3 t...
|
|
WO/2023/233994A1 |
The purpose of the present invention is to provide a pharmaceutical composition for treating or preventing diseases such as pulmonary diseases (excluding pulmonary fibrosis), renal diseases (excluding renal fibrosis), reproductive dysfun...
|
|
WO/2023/234583A1 |
The present invention relates to a pharmaceutical composition for preventing, improving, or treating renal fibrosis, and more specifically, to a pharmaceutical composition and a health functional food for preventing, improving, or treati...
|
|
WO/2023/234312A1 |
Antibody preparations for treating autoimmune-type diseases such as autoimmune diseases, allergic diseases, and kidney diseases in which autoimmunity is involved have been proposed, but the administration route thereof has been limited t...
|
|
WO/2023/234759A1 |
The present invention relates to a sulfanone derivative or a pharmaceutically acceptable salt thereof, and a composition containing the derivative as an active ingredient for the prevention or treatment of cancer, and the sulfanone deriv...
|
|
WO/2023/230339A1 |
Described herein is a method for treating, ameliorating and/or preventing polycystic kidney disease in a subject in need thereof. The method including administering to the subject an effective amount of a compound that downregulates GLIS...
|
|
WO/2023/230167A1 |
Described herein is a method of ameliorating and/or preventing autosomal dominant polycystic kidney disease (ADPKD) or a polycystic liver disease (PCLD) in a subject in need thereof. The method includes administering to the subject an ef...
|
|
WO/2023/228027A1 |
A controlled release pharmaceutical composition for oral administration comprising a therapeutically effective amount of mirabegron or a pharmaceutically acceptable salt thereof, as an active ingredient, a hydrogel-forming polymer, as re...
|
|
WO/2023/227070A1 |
The present disclosure relates to a double-stranded ribonucleic acid for inhibiting C3 gene expression, a modifier, a conjugate, and a use thereof. Specifically, the present disclosure relates to a double-stranded ribonucleic acid, a dou...
|
|
WO/2023/228971A1 |
Provided is a novel preventative/therapeutic agent which is linked to the complete curing and treatment of IgA nephropathy. This IgA nephropathy preventative/therapeutic agent targets tonsillar indigenous bacteria derived from an anti-...
|
|
WO/2023/229438A1 |
The present invention relates to a microfluidic reactor for producing microcapsules and external stimuli-responsive microcapsules produced by using same and, more specifically, to: a microfluidic reactor capable of effectively producing ...
|
|
WO/2023/224055A1 |
The present invention addresses the problem of providing a pharmaceutical composition for use in a therapeutic or prophylactic method for kidney injury. The problem can be solved by a pharmaceutical composition for use in a therapeutic...
|
|
WO/2023/224128A1 |
The present invention relates to a pharmaceutical composition for treating or preventing fibrosis, the pharmaceutical composition containing a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.
|
|
WO/2023/225445A1 |
The present disclosure relates to compositions and methods for increasing the level of Klotho in a cell or in a subject and in particular to compositions and methods for treating diseases or conditions associated with Klotho. The methods...
|
|
WO/2023/225163A1 |
Provided herein are methods of treating focal segmental glomerulosclerosis (FSGS), comprising administering a therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, to a subject in need thereof. Al...
|
|
WO/2023/223309A1 |
The present invention provides novel stimulator of IFN genes inhibitors and methods of using same, such as for treating inflammatory diseases.
|
|
WO/2023/225334A1 |
Provided are methods of treating subjects in need of an anti-fibroblast growth factor receptor 4 (anti-FGFR4) therapy. The methods comprise administering to the subjects a therapeutically effective amount of a peroxisome proliferator-act...
|
|
WO/2023/222865A1 |
The present invention relates to an azolo compound of Formula (I) for use in the treatment of fibrosis, wherein the azolo compounds normalizes collagen I mRNA-levels of TGFB-activated fibroblasts and reverses collagen production to the n...
|
|
WO/2023/217126A1 |
Provided in the present invention is a method for preparing a renal epithelial precursor-like cell, comprising the following steps: providing primary renal cells, placing the primary renal cells into a reprogramming medium for dedifferen...
|
|
WO/2023/218278A1 |
The present disclosure provides long-acting gene therapy methods to treat overactive bladder (OAB) and symptoms thereof, or to ameliorate symptoms thereof, comprising the administration of URO-902, a pharmaceutical composition comprising...
|
|
WO/2023/217125A1 |
Provided in the present invention are a prostate precursor-like cell, a cell preparation, a preparation method therefor and the use thereof. The preparation method comprises the following steps: S0: providing primary prostate cells; and ...
|
|
WO/2023/217020A1 |
Disclosed in the present invention are an immunoglobulin κ-type light chain (Vκ4-1-IgLC) polypeptide having a unique Vκ4-1 and the use thereof. The amino acid sequence of the Vκ4-1-IgLC polypeptide is as shown in SEQ ID NO.1, and the...
|
|
WO/2023/217179A1 |
Provided is use of mannose in inhibiting pyroptosis or relieving toxic and side effects of a chemotherapy drug, which relates to the field of medical science and technologies. Mannose inhibits pyroptosis induced by a chemotherapy drug, s...
|
|
WO/2023/217170A1 |
The present disclosure relates to use of a BTK inhibitor for treating disease. Specifically, the present disclosure relates to use of the BTK inhibitor in the preparation of a drug for preventing or treating membranous nephropathy, prote...
|
|
WO/2023/217121A1 |
Provided are a biological formulation containing renal precursor-like cells, and a preparation method and application therefor. The biological formulation comprises renal precursor-like cells positively expressing CD133, CD24 and CD44, h...
|
|
WO/2023/219127A1 |
The present invention provides a pharmaceutical composition which is for use in the treatment or prevention cystic disease and which comprises, as an active component, a compound that inhibits a phosphate transporter.
|
|
WO/2023/219361A1 |
The present invention relates to a composition comprising the compound of chemical formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient for the prevention or treatment of fibrotic diseases. The composition acco...
|
|
WO/2023/216926A1 |
Disclosed is a new use of CX-5461 in the preparation of a drug for treating immune rejection of kidney transplants. In the present invention, research shows that CX-5461 can significantly reduce immune rejection of kidney transplants. Sp...
|
|
WO/2023/220357A1 |
The present disclosure provides methods for treating or preventing loss of organ function due to chronic organ or tissue diseases by administering to a subject an effective amount of a TLR4 agonist, such as an MPLA-like compound. More pa...
|
|
WO/2023/215513A1 |
Disclosed herein are methods and systems for characterization, diagnosis, and treatment of cancer. Aspects of the present disclosure are directed to methods for prediction and identification of various molecular features of cancer using ...
|
|
WO/2023/215378A1 |
Provided herein are compounds and compositions thereof for modulating hepatocyte growth factors. In some embodiments, the compounds and compositions are provided for treatment of diseases, including fibrosis.
|
|
WO/2023/215367A1 |
Provided herein are compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein Z1, Z2, Z3, R1, R2, R3, and n are as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a comp...
|
|
WO/2023/215196A1 |
Disclosed herein are autotaxin inhibitor compounds, polymorphic forms, pharmaceutical compositions, and the method of use and preparation thereof. Some embodiments relate to crystalline forms of Compound 1 and salts thereof.
|
|
WO/2023/213264A1 |
The present invention relates to a novel oleanamide derivative for activating a KEAP/NRF2/ARE signaling pathway. The compound of the present invention is represented by general formula (I), wherein L, R3, R4, Z, and n are set forth in th...
|
|
WO/2023/209186A1 |
The present disclosure relates to peptide fragments derived from interleukin-4 (IL-4) for the treatment of diabetic nephropathy.
|
|
WO/2023/210741A1 |
The present invention addresses the problem of providing a medicine capable of treating and/or preventing a disease associated with oxidative stress through the inhibition of a protein-protein interaction between Keap1 and Nrf2 to activa...
|
|
WO/2023/210599A1 |
The present invention provides a compound represented by general formula[1] and having a DDR1 kinase inhibitory activity, a pharmaceutically acceptable salt of the compound, or a solvate of the compound or the pharmaceutically acceptable...
|
|
WO/2023/209555A1 |
Approved drug products and methods of treating a prostate cancer with an approved drug product are disclosed herein
|
|
WO/2023/207545A1 |
The present invention provides an activated gain-of-function mutant of branched-chain amino acid transaminase 1 (BCAT1), and use thereof. In particular, the present invention provides a human BCAT1E61A gain-of-function activated mutant p...
|
|
WO/2023/212518A1 |
Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.
|
|
WO/2023/210740A1 |
The present invention addresses the problem of providing a medicinal drug that can treat and/or prevent diseases linked to oxidative stress, by inhibiting the protein-protein interaction between Keap1 and Nrf2 to activate Nrf2. The prese...
|
|
WO/2023/208187A1 |
Provided in the present invention are a compound represented by formula (I), and a racemate, stereoisomer, tautomer, solvate, polymorph, or pharmaceutically acceptable salts thereof. The compound has good prostate tumor cell proliferatio...
|
|
WO/2023/203791A1 |
One purpose of the present disclosure is to provide a novel pharmaceutical composition, preferably a pharmaceutical composition capable of adsorbing a variety of disease-causing substances in vivo. A pharmaceutical composition that com...
|
|
WO/2023/202583A1 |
Disclosed are an FXR regulator and use thereof, and specifically disclosed are a compound represented by formula I, or a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, ...
|
|
WO/2023/203248A1 |
The invention relates to an apical sodium-dependent bile acid transporter (ASBT) inhibitor for use in the treatment of a liver or renal disease or disorder, wherein the ASBT inhibitor is administered subcutaneously. Such administration a...
|
|
WO/2023/202102A1 |
The present invention relates to the technical field of biomedicine, it has been found in the present invention that a compound shown in formula I, or an optical isomer or racemate thereof, or a solvate thereof, or a pharmaceutically acc...
|
|
WO/2023/205415A1 |
Provided are pharmaceutical compositions comprising a pharmaceutically acceptable carrier or diluent and a compound represented by Formula (I): or pharmaceutically acceptable salts thereof, which are useful for the activation of TFEB and...
|
|
WO/2023/205704A1 |
Embodiments include intravesical therapies for the treatment of ailments such as urinary system disorders. A controlled release drug delivery system is administered into the urinary bladder of a patient. Controlled release particles in t...
|
